TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6758224
Drug: Fansidar (two-tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fansidar (two-tablet regimen)
Study: 6758224
Drug: Fansidar (three-tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fansidar (three-tablet regimen)
Study: 24462073
Drug: High-dose statins
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose statins (atorvastatin 80 mg or rosuvastatin 20 mg)
Study: 24462073
Drug: Low-dose statins
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose statins or no statins
Study: 24462073
Drug: High-dose statins
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose statins (after propensity score adjustment)
Study: 24462073
Drug: Low-dose statins
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose statins or no statins (after propensity score adjustment)
Study: 17852631
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (betamethasone-dipropionate cream)
Study: 7502226
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy (platinum-based combination chemotherapy)
Study: 2278549
Drug: Ayurvedic drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayurvedic drug treatments for three months
Study: 28276148
Drug: Follicle flushing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follicle flushing three times with 2 ml in each follicle
Study: 24841733
Drug: Intralesional tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional tetracycline 2% injection
Study: 17196795
Drug: SSRIs with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRIs with hormonal therapy (HT)
Study: 17196795
Drug: SSRIs without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SSRIs without hormonal therapy (HT)
Study: 11227936
Drug: Rectal pressure-volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal pressure-volume measurement with a compliant balloon
Study: 11227936
Drug: Rectal impedance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal impedance planimetry
Study: 9781630
Drug: ACTH infusion
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH infusion (0.25 mg Cosyntropin intravenously over 240 minutes) after hypoglycemic insulin clamp (1 mU/kg/min)
Study: 9781630
Drug: ACTH infusion
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH infusion (0.25 mg Cosyntropin intravenously over 240 minutes) after euglycemic clamp
Study: 30526281
Drug: Antithrombotic drug
Normalized name: Heparin group antithrombotic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic drug use (either antiplatelets or anticoagulants)
Study: 30526281
Drug: Delay in
Normalized name: Delayed Release Oral Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delay in surgery after cessation of antiplatelet drug
Study: 26165370
Drug: Non-specific skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-specific skin points treatment (Control)
Study: 17214754
Drug: Range-of-motion exercise
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Range-of-motion exercise programme (4-week, twice-per-day, 6 days-per-week) supervised by a Registered Nurse
Study: 17214754
Drug: Range-of-motion exercise
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Range-of-motion exercise programme (4-week, twice-per-day, 6 days-per-week) with physical assistance from a Registered Nurse
Study: 11704162
Drug: Venlafaxine (50-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (50-200 mg/day)
Study: 9791141
Drug: Triple-drug therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-drug therapy (indinavir, zidovudine, lamivudine)
Study: 2756516
Drug: Nifuroxazide 400
Normalized name: nifuroxazide 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifuroxazide 400 mg twice a day
Study: 2756516
Drug: Nifuroxazide 1200
Normalized name: nifuroxazide
DrugBank: Nifuroxazide (DB13855)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifuroxazide 1200 mg once a day
Study: 18996523
Drug: ABT-335 +
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-335 + rosuvastatin 10 mg
Study: 18996523
Drug: ABT-335 +
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-335 + rosuvastatin 20 mg
Study: 17026664
Drug: Antioxidant preparation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant preparation applied to forearm skin
Study: 17026664
Drug: Control area
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control area (no antioxidant preparation)
Study: 15576014
Drug: Sustained-release lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release lithium carbonate matrix tablets containing 450 mg LC with 15% CP
Study: 15576014
Drug: Sustained-release commercial
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release commercial tablet (Eskalith CR)
Study: 11094787
Drug: 5 mg/m3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/m3 zinc oxide inhalation for naive subjects on 1 or 3 days
Study: 11094787
Drug: Zinc oxide
Normalized name: Zinc Oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc oxide inhalation for sheet metal workers on 1 day
Study: 11094787
Drug: Control furnace
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control furnace gas inhalation for sheet metal workers on another day
Study: 9125668
Drug: Diltiazem extended-release
Normalized name: diltiazem Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem extended-release 240 mg once daily for 8 weeks
Study: 8385161
Drug: OPC-21268 10
Normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC-21268 10 mg
Study: 8385161
Drug: OPC-21268 50
Normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC-21268 50 mg
Study: 8385161
Drug: OPC-21268 300
Normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC-21268 300 mg, 3 times daily for 7 days
Study: 8385161
Drug: OPC-21268 100
Normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC-21268 100 mg single doses
Study: 3898834
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Sucralfate + Cimetidine)
Study: 30607985
Drug: Vestibular rehabilitation
Normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vestibular rehabilitation therapy (VRT)
Study: 27510395
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 μg/kg over 10 minutes followed by a 0.5 μg/kg/hr infusion)
Study: 27510395
Drug: Fentanyl (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (1.0 μg/kg over 1 minute followed by a 0.4 μg/kg/hr infusion)
Study: 27510395
Drug: Remifentanil (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (1.0 μg/kg over 1 minute followed by a 0.08 μg/kg/min infusion)
Study: 20033417
Drug: Organically produced
Normalized name: Organic germanium
DrugBank: Propagermanium (DB17608)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Organically produced apples (500 g/day for 4 weeks)
Study: 20033417
Drug: Conventionally produced
Normalized name: RECOMBINANT DNA DERIVED B-DOMAIN DELETED PORCINE BLOODCOAGULATION FACTOR VIII ANALOGUE, PRODUCED IN BHK21 CELLS: DES-(753-1418)-BLOOD-COAGULATION FACTOR VIII (PROCOAGULANT COMPONENT) SUS SCROFA, GLYCOSYLATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventionally produced apples (500 g/day for 4 weeks)
Study: 18525384
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g of green tea
Study: 10431942
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg of caffeine
Study: 8735325
Drug: Blood samples
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood samples drawn from heparinized double-lumen Hickman catheters after discarding 5, 10, 15, 20, and 25 ml of blood.
Study: 1836921
Drug: SmithKline Beecham's
Approvals — FDA: no, EMA: no, PMDA: no
Description: SmithKline Beecham's recombinant DNA (SB rDNA) vaccine (Engerix‐B) at its adult dose of 20 micrograms
Study: 1836921
Drug: MSD rDNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSD rDNA vaccine
Study: 6407361
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (IVm) - 10 mg of morphine sulfate in 10 ml of saline
Study: 6407361
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (Em) - 10 mg of morphine sulfate in 10 ml of saline
Study: 25269764
Drug: Trigger Point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trigger Point Manual Therapy (TrP MT)
Study: 19669016
Drug: Methadone (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (0.1 mg.kg‐1)
Study: 19669016
Drug: Clonidine (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (2.0 (1/4)g.kg‐1)
Study: 2643046
Drug: Prednisone (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (45 mg per square meter of body-surface area, given on alternate days for six months)
Study: 29575037
Drug: PMBL® Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMBL® Tablet
Study: 26335635
Drug: HIV nosode
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV nosode (30c potency pills), administered orally once a week for 4 weeks
Study: 26335635
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical pills), administered orally once a week for 4 weeks
Study: 17563395
Drug: Anastrozole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (1 mg/d)
Study: 16990386
Drug: Eculizumab (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab (600 mg weekly for 4 weeks, followed by 900 mg one week later and then 900 mg every other week through week 26)
Study: 15316551
Drug: Rotary preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotary preparations
Study: 8355458
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion (Totamine, 6 to 8 mg/kg/min for 90 to 120 min)
Study: 8355458
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion (Totamine) with perindoprilat (2 mg i.v.)
Study: 8355458
Drug: Perindoprilat (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindoprilat (2 mg i.v.) alone
Study: 8355458
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion (Totamine)
Study: 8355458
Drug: Perindoprilat (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindoprilat (2 mg i.v.)
Study: 2451409
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose bunazosin (3 mg/day for the first week followed by 4.5 mg/day for the next three weeks)
Study: 2451409
Drug: Middle dose
Normalized name: wheat middlings extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle dose bunazosin (1.5 mg/day for the first week to 3.0 mg/day for the next three weeks)
Study: 2451409
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose bunazosin (0.15 mg/day for the first week to 1.5 mg/day for the next three weeks)
Study: 2451409
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0.125 mg/day for the entire four weeks)
Study: 16644023
Drug: Mitoxantrone (MX)
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitoxantrone (MX) therapy
Study: 12729289
Drug: Iron supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplements 2 ng/kg/day (group IA)
Study: 12729289
Drug: Iron syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron syrup 6 mg/kg/day (group II)
Study: 11220944
Drug: Multimodal approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal approach including spinal or spinal-epidural anesthesia, preoperative epidural opioid analgesics, and administration of drugs affecting NMDA receptors (ketamine, magnesium sulfate)
Study: 8973523
Drug: Rhesus tetravalent
Normalized name: dengue virus live antigen, CYD serotype 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhesus tetravalent rotavirus vaccine (RRV‐TV)
Study: 8973523
Drug: Serotype G1
Normalized name: Rotavirus serotype G1 Ag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotype G1 monovalent rotavirus vaccine (RRV‐S1)
Study: 8973523
Drug: Post-vaccination neutralizing
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-vaccination neutralizing antibody titers to Wa
Study: 1349112
Drug: Oral ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ofloxacin 400 mg twice daily
Study: 1349112
Drug: Parenteral combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral combination antibiotics (amikacin 15 mg/kg daily, plus carbenicillin, cloxacillin, or piperacillin)
Study: 30131229
Drug: Scheduled repetitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled repetitive 24‐hour levosimendan infusions (LEVO) at tailored doses (0.05‐0.2 μg/kg/min)
Study: 27467714
Drug: Baclofen (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (30 mg/day for 3 months)
Study: 18764999
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg letrozole
Study: 11856089
Drug: OAC250 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC250 group (omeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 250 mg)
Study: 11856089
Drug: OAC500 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC500 group (omeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg)
Study: 11856089
Drug: OTC group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTC group (omeprazole 20 mg, tinidazole 500 mg, clarithromycin 500 mg)
Study: 7776513
Drug: Diltiazem 4
Normalized name: dilTIAZem 420 mg/24 hours oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 4 mcg.kg‐1.min‐1 constant infusion
Study: 7776513
Drug: Diltiazem 2
Normalized name: diltiazem 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 2 mcg.kg‐1.min‐1 constant infusion
Study: 30922154
Drug: PHYLLPRO™, 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHYLLPRO™, 750 mg/day for 10 days
Study: 23522182
Drug: AZD1656 (40-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1656 (40-200 mg)
Study: 23522182
Drug: AZD1656 (20-140
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1656 (20-140 mg)
Study: 23522182
Drug: AZD1656 (10-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1656 (10-80 mg)
Study: 11035612
Drug: Didanosine (ddI)
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Didanosine (ddI) once daily (400 mg/day, 250 mg/day if body weight <60 kg)
Study: 11035612
Drug: Didanosine (ddI)
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Didanosine (ddI) twice daily (400 mg/day, 250 mg/day if body weight <60 kg)
Study: 11035612
Drug: Didanosine (ddI)
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Didanosine (ddI) once daily and twice daily
Study: 6496450
Drug: 3 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 micrograms doses of heat-inactivated hepatitis B surface antigen (HBsAg) at one-month intervals (trial A)
Study: 6496450
Drug: 5 different
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 different dosages of the vaccine (trial B)
Study: 30215690
Drug: Teprotumumab, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teprotumumab, a monoclonal inhibitory antibody targeting IGF‐IR
Study: 29606129
Drug: Life Steps-Drug
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Life Steps-Drug Use (LS-DU) intervention
Study: 25415159
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate (40 mg vaginally)
Study: 20530110
Drug: TPN with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN with heparin (0.5 IU/ml)
Study: 20530110
Drug: TPN without
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN without heparin
Study: 18842911
Drug: Inhaled steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled steroids treatment based on eNO and sEos levels
Study: 18842911
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment based on symptoms and function
Study: 7723340
Drug: Allopurinol 200
Normalized name: allopurinol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 200 mg intravenously 1 hour preoperatively
Study: 28110424
Drug: Caffeine group
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine group (n = 15), coffee containing 222 mg of caffeine 2 hours before catheterization
Study: 27273884
Drug: Cycle Ergometry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle Ergometry (CE) with 10 g protein/46 g carbohydrate drink (223 kcal)
Study: 27273884
Drug: Combat rations
Normalized name: Provita Combat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combat rations supplemented with 1000 kcal/day from 20 g protein- or 48 g carbohydrate-based bars
Study: 20345030
Drug: Fixed-point spin
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-point spin reduction of spinal manipulation therapy
Study: 20345030
Drug: Dialectical prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical prescription
Study: 18631903
Drug: MPT-OA plus
Normalized name: MPT-0L055
DrugBank: MPT-0L055 (DB17136)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPT-OA plus standard treatment
Study: 12362781
Drug: Micro-encapsulated ferrous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-encapsulated ferrous fumarate (12.5 mg of elemental iron)
Study: 10355573
Drug: Further chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Further chemotherapy (3 courses of MIP: cisplatin 50 mg/m2, ifosfamide 3 g/m2, mitomycin C 6 mg/m2)
Study: 2792112
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg nicardipine
Study: 7732981
Drug: Open-label nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label nicardipine (30 or 40 mg three times a day for 1 week)
Study: 1975199
Drug: Atipamezole 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atipamezole 100 mg i.v.
Study: 1975199
Drug: Atipamezole 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atipamezole 30 mg i.v.
Study: 1975199
Drug: Atipamezole 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atipamezole 10 mg i.v.
Study: 1975199
Drug: Atipamezole (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atipamezole (oral dosing)
Study: 25709097
Drug: Δ(9)‐THC 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Δ(9)‐THC 0.03 mg/kg
Study: 25709097
Drug: Δ(9)‐THC 0.015
Approvals — FDA: no, EMA: no, PMDA: no
Description: Δ(9)‐THC 0.015 mg/kg
Study: 17484218
Drug: Live pentavalent
Normalized name: rotavirus, live pentavalent (RV5) Oral Vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live pentavalent rotavirus vaccine (PRV)
Study: 15754631
Drug: Topotecan (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan (1.5 mg/m2 daily for 5 days, repeated 5 times with 21-day intervals)
Study: 11586196
Drug: Laparoscopic skills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic skills training (30 minutes daily for 10 days)
Study: 9704732
Drug: VACOP-B for
Approvals — FDA: no, EMA: no, PMDA: no
Description: VACOP-B for 12 weeks plus high-dose therapy (HDT) and autologous bone marrow transplantation (ABMT)
Study: 7988262
Drug: Preoperative mitomycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative mitomycin, vinblastine, and cisplatin (MVP) chemotherapy (cisplatin 120 mg/m2, mitomycin 8 mg/m2 on day 1 + 29, vinblastine 4.5 mg/m2 on days 1, 15, 22, and 29, and 2.0 mg/m2 on day 8)
Study: 31923105
Drug: Active tACS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active tACS (20 daily 40-min sessions at 77.5 Hz, 15 mA)
Study: 31634198
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral tenofovir disoproxil fumarate (TDF) for pre‐exposure prophylaxis (PrEP)
Study: 26231324
Drug: Coaching about
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coaching about dietary and medication adherence
Study: 20218321
Drug: Qianliean Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qianliean Suppository (1 pill per night for 28 days)
Study: 20218321
Drug: Yejuhua Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yejuhua Suppository (1 pill per night for 28 days)
Study: 20218321
Drug: Qianliean Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qianliean Suppository
Study: 20218321
Drug: Yejuhua Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yejuhua Suppository
Study: 3124680
Drug: Zidovudine (AZT),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (AZT), 200 or 250 mg every 4 hours
Study: 26999045
Drug: Antibiotic-impregnated central
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic-impregnated central venous catheters (CVCs)
Study: 17851757
Drug: Tipifarnib 300
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tipifarnib 300 mg (TL)
Study: 17851757
Drug: Placebo (L)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (L)
Study: 10633513
Drug: 40% nitrous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% nitrous oxide/60% oxygen inhalation
Study: 10633513
Drug: 100% oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% oxygen inhalation
Study: 8602667
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg x kg(-1) edrophonium